ArticleBMC pregnancy and childbirth2025
Assessment of fetal left ventricular function in pregnancies with Anti-Ro/SSA or Anti-La/SSB antibodies using velocity vector imaging.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrauterine exposure to anti SSA/Ro and anti SSB/La antibodies has been associated with the development of fetal congenital heart block and, in severe cases, fetal demise. Therefore, early and accurate assessment of fetal cardiac function is of critical importance. Velocity vector imaging (VVI) is an emerging technique capable of providing a detailed assessment of cardiac function. This study aimed to assess and compare left ventricular myocardial function in fetuses of pregnant women with and without anti-Ro/SSA or anti-La/SSB antibodies, and to explore the correlation between global myocardial function parameters and gestational age using VVI technology.
methodsA total of 90 pregnant women with anti-Ro/SSA or anti-La/SSB antibodies were enrolled as the study group, and 90 pregnant women without autoimmune antibodies were included as the control group. Participants were stratified into four subgroups based on their gestational age. Fetal left ventricular regional and global velocities, strain, strain rate, and additional myocardial parameters were measured using ultrasound-based VVI.
resultsSeveral regional longitudinal myocardial parameters of the fetal left ventricle were significantly lower in the study group compared to the control group (p < 0.05). Similarly, global longitudinal myocardial parameters were significantly reduced in the study group than those in the control group (p < 0.05). In both groups, the global peak velocity of fetal left ventricle increased with advancing gestational age. However, no statistically significant difference was observed between gestational age and either strain or peak strain rate (p > 0.05).
conclusionVVI-derived parameters effectively reflect early alterations in myocardial mechanics in fetuses exposed to anti-Ro/SSA or anti-La/SSB antibodies. This modality enables quantitative evaluation of both regional and global myocardial motion and may assist clinicians in timely identification of myocardial dysfunction. Moreover, global VVI parameters hold potential as early indicators of myocardial impairment in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.